FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Feuerbach Mark		 2. Issuer Name and Ticker or Trading Symbol

Innophos Holdings, Inc. [ IPHS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Interim CFO
(Last)          (First)          (Middle)

259 PROSPECT PLAINS RD., BUILDING A		 3. Date of Earliest Transaction (MM/DD/YYYY)

2/7/2020
(Street)

CRANBURY, NJ 08512
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share 2/7/2020  D  32078 D (1)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Shares  (2)2/7/2020  D     968   (2) (2)Common Stock 968  (2)0 D  
Performance Shares  (2)2/7/2020  D     1263   (2) (2)Common Stock 1263  (2)0 D  
Performance Shares  (2)2/7/2020  D     3893   (2) (2)Common Stock 3893  (2)0 D  
Stock Option (Right to Buy) $50.12 2/7/2020  D     352   (3)3/30/2022 Common Stock 352  (3)0 D  
Stock Option (Right to Buy) $54.59 2/7/2020  D     946   (3)3/29/2023 Common Stock 946  (3)0 D  
Stock Option (Right to Buy) $55.49 2/7/2020  D     2688   (3)3/27/2024 Common Stock 2688  (3)0 D  
Stock Option (Right to Buy) $49.54 2/7/2020  D     3510   (3)5/8/2025 Common Stock 3510  (3)0 D  
Stock Option (Right to Buy) $31.11 2/7/2020  D     8694   (3)4/1/2026 Common Stock 8694  (3)0 D  
Stock Option (Right to Buy) $52.51 2/7/2020  D     4319   (3)4/3/2027 Common Stock 4319  (3)0 D  
Stock Option (Right to Buy) $39.28 2/7/2020  D     6937   (3)4/2/2028 Common Stock 6937  (3)0 D  
Stock Option (Right to Buy) $31.03 2/7/2020  D     28171   (3)4/1/2029 Common Stock 28171  (3)0 D  
Explanation of Responses:
(1) Pursuant to the Agreement and Plan of Merger among the Issuer, Iris Parent LLC ("Parent") and Iris Merger Sub 2019, Inc. dated as of October 20, 2019, the Issuer became a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time") on February 7, 2020. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), (including each restricted share) was automatically converted into the right to receive $32.00 in cash, without interest.
(2) Each performance share represented the right to receive shares of Common Stock, subject to the achievement of certain performance measures. Pursuant to the Merger Agreement, as of the Effective Time, each performance share outstanding and unvested immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to (i) the target number of shares of Common Stock subject to such performance share multiplied by (ii) $32.00, plus the amount of any accrued but unpaid dividend equivalents associated with such performance share, less any applicable tax withholding.
(3) Pursuant to the Merger Agreement, each stock option outstanding and unexercised immediately prior to the Effective Time immediately vested (if unvested) and was converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such stock option multiplied by (ii) the excess of (x) $32.00 over (y) the exercise price payable in respect of each share of Common Stock subject to such stock option, less any applicable tax withholding; provided, however, that stock options with an exercise price equal to or greater than $32.00 were cancelled without the right to receive any cash payment in consideration thereof.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Feuerbach Mark
259 PROSPECT PLAINS RD., BUILDING A
CRANBURY, NJ 08512

Interim CFO
Signatures
/s/ Joshua S. Horenstein, as Attorney-in-Fact2/7/2020
**Signature of Reporting PersonDate
Innophos (NASDAQ:IPHS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Innophos Charts.
Innophos (NASDAQ:IPHS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Innophos Charts.